JAB-21822
JAB-21822-1001
Phase 2 small_molecule active
Quick answer
JAB-21822 for advanced solid tumors with KRAS G12C mutation is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- advanced solid tumors with KRAS G12C mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active